RE:4050 no proofHmmm!
I'm not sure about that.
Concept of efficacity can be see with biomarkers.
We already have a phase I result in DKD for the toxicity. Don't forget they already were able to collect blood sample and urine from that phase I.
I would imagine that they can easily do the analysis of those biomarkers and have a pretty good idea.
I don't think they would go in DKD phase 1b/II and in metabolic syndrome in a phase I trial at the same time if they would had no clue.